Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025
Request Sample
Pre-order Enquiry
Request Customization
Check Discounts
Description
Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemotherapy. Its product was first developed by Amgen in the United States. In 2012, PEG-rhG-CSF was approved in China. By 2020, the main manufacturers of PEG-rhG-CSF in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.
According to Researcher's market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.
CRI analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China's medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.
Topics Covered:
-The impact of COVID-19 on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Sales value of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
- Competitive landscape of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
- Analysis on factors affecting the development of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prospect of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025
Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemotherapy. Its product was first developed by Amgen in the United States. In 2012, PEG-rhG-CSF was approved in China. By 2020, the main manufacturers of PEG-rhG-CSF in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.
According to Researcher's market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.
CRI analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China's medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.
Topics Covered:
-The impact of COVID-19 on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Sales value of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
- Competitive landscape of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
- Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
- Analysis on factors affecting the development of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
- Prospect of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
CRI-18360562
28-May-2021
50
28-May-2021
50
License
